[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amyloidosis-cardiac\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amyloidosis-cardiac":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,84,106,129,157,186,216,238,263,308],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100476869","subclinical-transthyretin-cardiac-amyloidosis-in-v122i-ttr-carriers-100476869",false,"NCT05489549","Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers","Identifying Subclinical Transthyretin Cardiac Amyloidosis in Asymptomatic Carriers of the V122I TTR Allele","(V122I TTR carriers and carriers of other pathogenic TTR alleles (or matched non-carriers))\n\nInclusion Criteria:\n\n* Men and women ages 30-80 who are carriers of pathogenic TTR alleles (or matched non-carriers) without history of HF (this will be assessed by study personnel) and defined as: a) No history of hospitalization within the previous 12 months for management of HF; b) Without an elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or c) No clinical diagnosis of HF from a treating clinician\n* Signed informed consent\n\nExclusion Criteria:\n\n* A self-reported history or clinical history of HF\n* Other known causes of cardiomyopathy\n* History of light-chain cardiac amyloidosis\n* Prior type 1 myocardial infarction (non-ST segment elevation myocardial Infarction {NSTEMI} or ST-elevation myocardial infarction {STEMI})\n* Cardiac transplantation\n* Body weight \\>250 lbs\n* Estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2\n* Inability to safely undergo CMRI\n\n(For participants with symptomatic hATTR-CA, we will enroll probands with HF from Aim 1 or patients with suspected symptomatic hATTR-CA from the three study sites.)\n\nInclusion Criteria:\n\n* Men and women ages 30-80 who have symptomatic hATTR-CA as determined by a history of HF (this will be assessed by study personnel) and defined as: a) History of hospitalization within the previous 12 months for management of HF; b) An elevated B-type natriuretic peptide level ≥100 pg\u002FmL or NT-proBNP ≥360 pg\u002FmL within the previous 12 months; or c) A clinical diagnosis of HF from a treating clinician.\n* Have an established or suspected diagnosis of hATTR-CA based on either a) Biopsy confirmed by Congo red (or equivalent) staining with tissue typing with immunohistochemistry or mass spectrometric analysis or immunoelectron microscopy, OR b) positive technetium-99m (99mTc)-pyrophosphate or -bisphosphonate scan, combined with accepted laboratory criteria without abnormal M-protein.\n* TTR gene sequencing that is pending or that is confirming the pathogenic TTR variant\n* Signed informed consent\n\nExclusion Criteria:\n\n* Other known causes of cardiomyopathy\n* History of light-chain cardiac amyloidosis\n* Cardiac transplantation\n* Liver transplantation\n* Previous treatment with a TTR stabilizer (tafamidis, acoramidis) within the prior 14 days or TTR any silencer (inotersen, patisiran, eplontersen)\n* Estimated glomerular filtration rate ≤30 mL\u002Fmin\u002F1.73 m2","ALL","30 Years","80 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the transthyretin (TTR) protein. Virtually exclusive to Blacks, this is the most common cause of hereditary cardiac amyloidosis (hATTR-CA) worldwide. hATTR-CA leads to worsening heart failure (HF) and premature death. Fortunately, new therapies that stabilize TTR improve morbidity and mortality in hATTR-CA, especially when prescribed early in the disease. However, hATTR-CA is often diagnosed at an advanced stage and conventional diagnostic tools lack diagnostic specificity to detect early disease.\n\nThe overall objectives of this study are to determine the presence of subclinical hATTR-CA and to identify biomarkers that indicate amyloid progression in V122I TTR carriers. The central hypothesis of this proposal is that hATTR-CA has a long latency period that will be detected through subclinical amyloidosis imaging and biomarker phenotyping.\n\nThe central hypothesis will be tested by pursuing 2 specific aims: Aim 1) determine the association of V122I TTR carrier status with CMRI evidence of amyloid infiltration; Sub-aim 1) determine the association of V122I TTR carrier status with cardiac reserve; Aim 2) determine the association between amyloid-specific biomarkers and V122I TTR carrier status; and Sub-aim 2) determine the association of amyloid-specific biomarkers with imaging-based parameters and evaluate their diagnostic utility for identifying subclinical hATTR-CA. In Aim 1, CMRI will be used to compare metrics associated with cardiac amyloid infiltration between a cohort of V122I TTR carriers without HF formed by cascade genetic testing and age-, sex-, and race-matched non-carrier controls. For Sub-Aim 1, a sub-sample of carriers and non-carrier controls enrolled in Aim 1 will undergo novel exercise CMRI to measure and compare cardiac systolic and diastolic reserve. Aim 2 involves measuring and comparing amyloid-specific biomarkers in V122I TTR carriers without HF with samples matched non-carriers (both from Aim 1) and individuals with symptomatic V122I hATTR-CA from our clinical sites. These biomarkers detect and quantify different processes of TTR amyloidogenesis and include circulating TTR, retinol binding protein 4, TTR kinetic stability, and misfolded TTR oligomers. Sub-aim 2 will establish the role of these biomarkers to detect imaging evidence of subclinical hATTR-CA disease.",[25,26,27,28,29],"Amyloidosis, Hereditary","Amyloidosis Cardiac","Amyloidosis, Familial","Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy","Transthyretin Gene Mutation",[31,32,33,34,35],"Amyloidosis","Transthyretin Amyloidosis","V122I TTR","p.Val142Ile TTR","Cardiac magnetic resonance imaging","RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-26","ACTUAL",{"date":42,"type":40},"2022-11-21",{"date":44,"type":21},"2027-06-30",{"name":46,"class":47},"University of Texas Southwestern Medical Center","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100639681","screening-characterization-and-longitudinal-follow-up-of-patients-with-cardiac-amyloidosis-100639681","NCT07577466","Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis","Inclusion Criteria:\n\n* Age \\> 18 years\n* Male and female patients undergoing clinically indicated diagnostic work-up for amyloidosis or with a previously confirmed diagnosis of cardiac amyloidosis prior to initiation of therapy\n* Presence of left ventricular wall thickness \\> 12 mm on transthoracic echocardiography and at least one \"red flag\" suggestive of cardiac amyloidosis (according to ESC 2021 criteria) or an otherwise clinically established suspicion of amyloidosis\n* Written informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Contraindications to cardiac MRI (e.g., metallic foreign bodies, older-generation pacemakers, severe obesity, claustrophobia)\n* Lack of written informed consent for study participation\n* Inability to comply with the study procedures","18 Years",{"count":57,"type":21},200,"Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function. Early diagnosis and targeted therapies are essential to improve patient outcomes. This prospective, single-center study aims to longitudinally follow patients with suspected cardiac amyloidosis to characterize disease progression and assess treatment effects. Participants will undergo cardiac magnetic resonance imaging (resting and exercise stress MRI), magnetic resonance spectroscopy, cardiopulmonary exercise testing (spiroergometry) and blood testing at baseline and at 6, 12, and 24 months",[26,60,61,62,63,64],"Heart Failure","Cardiac MRI","Spectroscopic Analysis","Diagnosis","Phenotyping",[61,66,67,68,69,70,71,72],"Exercise MRI","Magnetic Resonace Spectroscopy","Spirometry","Cardiopulmonary Exercise Testing","Disease Progression","Treatment Monitoring","Longitudinal Study","NOT_YET_RECRUITING","2026-05-04",{"date":76,"type":40},"2026-05-11",{"date":78,"type":21},"2026-06-15",{"date":80,"type":21},"2029-12-31",{"name":82,"class":47},"Heinrich-Heine University, Duesseldorf",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":83},"100535434","national-referral-center-study-of-transthyretin-amyloid-cardiomyopathyattr-patients-on-tafamidis-100535434","NCT06251778","NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis","NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis: Real World Prospective Study","NOTE-ATTR","Inclusion Criteria:\n\n* Diagnosis of ATTRwt amyloidosis.\n* 18 years or older;\n* evidence of cardiac involvement at echocardiography or cardiac MRI.\n* No known prior history of atrial fibrillation or major bradyarrhythmia (second degree atrioventricular block, third-degree atrioventricular block, high-grade atrioventricular block or alternating right and left branch block)\n* female patients who are postmenopausal for at least 1 year before the screening visit\n* patients on therapy or candidates for therapy with tafamidis 61 mg\n* voluntary written consent must be given before performance of any study-related procedure not part of standard medical care with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.\n\nExclusion Criteria:\n\n* Non-ATTR amyloidosis;\n* NYHA class III and IV;\n* Pregnant or nursing women;\n* Previous pacemaker implantation;\n* any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with a fully comprehension of the written consent form","99 Years",{"count":57,"type":21},"All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to Italian Medicines Agency regulations. C onsidering the significant risk of developing heart rhythm disturbances due to cardiac amyloidosis, especially in transthyretin form (ATTRwt), in routine clinical practice a stricter heart rhythm monitoring is recommended in ATTRwt patients. Moreover, particular attention is usually paid for those who present atrio-ventricular and\u002For intraventricular block at the baseline electrocardiogram. Data about rhythm disturbances and diuretic dose need will be collected during the planned physical examination every six months and the Holter ECG monitoring requested by the physician at the end of every planned clinical evaluation.",[31,26,96],"ATTR Amyloidosis Wild Type","2026-04-13",{"date":99,"type":40},"2026-04-16",{"date":101,"type":40},"2024-01-26",{"date":103,"type":21},"2027-01-26",{"name":105,"class":47},"Paolo Milani",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100606183","beamycon-biobank--data-registry-uz-leuven-100606183","NCT07172243","BE.Amycon Biobank & Data Registry UZ Leuven","BE.Amycon Biobank & Data Registry UZ Leuven: Human Body Material (HBM) Collection and Data Collection of Patients With Amyloidosis","Inclusion Criteria:\n\n* Provide consent and sign informed consent form\n* Age 18 years or older\n* Diagnosis of amyloidosis (suspected or confirmed, any subtypes)\n* For the prospective sample collection only: newly diagnosed (any subtype) or at relapse (AL amyloidosis)\n\nExclusion Criteria:\n\n* Not willing to sign informed consent\n* Not able to sign informed consent",true,{"count":115,"type":21},505,"The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank \"BE.Amycon biobank\" for future research and to collect clinical data of patients with amyloidosis in a database \"BE.Amycon data registry\".",[31,118,26],"AL Amyloidosis","2026-02-23",{"date":121,"type":40},"2026-02-27",{"date":123,"type":40},"2025-09-24",{"date":125,"type":21},"2030-01",{"name":127,"class":47},"Universitaire Ziekenhuizen KU Leuven",2,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":137,"conditions":138,"keywords":145,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":83},"100620597","multimodal-analysis-of-endomyocardial-biopsies-100620597","NCT07359690","Multimodal Analysis of Endomyocardial Biopsies","Inclusion Criteria:\n\n* Patients aged \\>18 years with a clinical indication for endomyocardial biopsy.\n* Patients capable of providing informed consent who have signed the consent form for participation in the study.\n\nExclusion Criteria:\n\n* Patients without a clinical indication for endomyocardial biopsy (EMB).\n* Pregnant individuals.\n* Patients incapable of providing informed consent.\n* Women of childbearing potential who are not using adequate contraception.",{"count":136,"type":21},216,"The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and thereby contribute to improving diagnosis and therapy.\n\nThe main aim is:\n\n-Identification of molecular profiles (e.g., proteome, lipidome, metabolome) and immune signalling profiles that are specifically associated with different myocardial diseases and the post-heart transplantation course.\n\nParticipants already receiving an endomyocardial biopsy as part of their regular medical care will be enrolled. An additional biopsy sample will be taken for the above mentioned research.",[139,140,141,142,26,143,144],"Heart Transplantation","Dilated Cardiomyopathy (DCM)","Hypertrophic Cardiomyopathy (HCM)","Myocarditis, Pericarditis","Cardiomyopathies","Sarcoidosis of the Heart",[146,147],"Endomyocardial biopsy","Multimodal analysis","2026-01-15",{"date":150,"type":40},"2026-01-22",{"date":152,"type":40},"2025-10-27",{"date":154,"type":21},"2028-09-30",{"name":156,"class":47},"University Hospital, Essen",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":113,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":164,"targetDuration":166,"studyType":22,"phases":4,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":83},"100617103","attr-amyloid-cardiomyopathy-characterization-of-extracellular-vesicles-as-potential-disease-stratifiers-and-prognostic-biomarkers-100617103","NCT07314268","ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers","EV-ATTR","Inclusion Criteria:\n\n* Adult patients aged 18 years or older;\n* Confirmed diagnosis of transthyretin cardiac amyloidosis (TTR-CA), with or without myocardial dysfunction, according to established diagnostic criteria;\n* Willingness to comply with study procedures and requirements;\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of other significant cardiac conditions that may interfere with study outcomes, such as severe coronary artery disease or major valvular disease;\n* Inability to provide informed consent or to participate in the required clinical assessments and examinations.",{"count":165,"type":21},70,"12 Months","This study explores whether extracellular vesicles (EVs) tiny particles released into the bloodstream by cells can serve as early and minimally invasive biomarkers for transthyretin amyloid cardiomyopathy (ATTR-CM). Because ATTR-CM is often diagnosed only after significant heart damage has occurred, there is an urgent need for earlier detection methods.\n\nThe study will enroll individuals with different clinical presentations of transthyretin amyloidosis, along with healthy controls. Participants will undergo blood sampling, cardiac imaging (including echocardiography, cardiac MRI, and scintigraphy when indicated), and molecular EV analysis.\n\nBy comparing EV profiles across groups, the study aims to determine whether these vesicles reflect early cardiac involvement, track disease progression, and support more accurate and timely diagnosis. Ultimately, this research seeks to improve clinical decision-making and patient outcomes in ATTR cardiomyopathy.",[169,26,25,170],"Wild-type ATTR Amyloidosis","Amyloidosis Transthyretin",[172,173,174,175,176],"Early Diagnosis","Serum Biomarkers","Transthyretin Amyloid Cardiomyopathy","ATTR","Vesicle Protein Signature","2025-12-16",{"date":179,"type":40},"2026-01-02",{"date":181,"type":40},"2024-10-18",{"date":183,"type":21},"2026-12-31",{"name":185,"class":47},"University of Sao Paulo General Hospital",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":196,"phases":197,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":83},"100601559","multimodality-cardiac-imaging-for-disease-progression-in-attr-cm-100601559","NCT07112066","Multimodality Cardiac Imaging for Disease Progression in ATTR-CM","Natural History of Cardiac Transthyretin Amyloidosis - Mechanistic Insights by Multimodality Imaging","FAPI-ATTR","Inclusion Criteria:\n\n* Participants with cardiac ATTR amyloidosis, as recently defined by multi-societal criteria, who are about to start tafamidis at the University Hospital Zurich\n\nExclusion Criteria:\n\n* Any other disease-modifying therapy (e.g. patisiran)\n* Ongoing supraventricular arrhythmia\n* Ventricular pacing\n* Prior septal myocardial infarction",{"count":195,"type":21},50,"INTERVENTIONAL",[198],"NA","The goal of this clinical trial is to investigate whether new imaging techniques can help us to better understand the cardiac amyloidosis. The disease can be slowed down with various medications (e.g., tafamidis, acoramidis, or vutrisiran). However, treatment is not effective in all patients-in about one-third of cases, the disease continues to progress. So far, we know little about the exact causes of this and what biological changes occur in the heart muscle.\n\nThe main question it aims to answer is:\n\nWill new imaging techniques help us understand the course of the cardiac amyloidosis?\n\nParticipants will have additional examinations:\n\n* At the beginning of the study: one additional heart ultrasound examination, one cardiac MRI and one cardiac PET, blood examination during the regular examination, questionnaires.\n* After a year: one additional heart ultrasound examination, one cardiac MRI and one cardiac PET, blood examination during the regular examination.\n\nTime required:\n\n* Heart ultrasound examination: 5-10 Minutes\n* Cardiac MRI: 2 hours\n* Cardiac PET: 2 hours\n* Questionnaires: 5-10 Minutes.",[26],[202,203,204,205,206],"cardiac ATTR amyloidosis","BMP4 protein, human","18F-FAPI-74","PET","CT","2025-12-01",{"date":209,"type":40},"2025-12-09",{"date":211,"type":40},"2025-10-20",{"date":213,"type":21},"2027-06",{"name":215,"class":47},"Dominik Benz",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":113,"sex":16,"minAge":55,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":196,"phases":225,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":83},"100413738","phase-4-ultrasound-therapy-in-cardiac-amyloidosis-100413738","NCT04667494","Ultrasound Therapy In Cardiac Amyloidosis","UTICA","Inclusion Criteria:\n\n* Age \\> 18 years for AL-CA, \\> 65 years for ATTR-CA, \\> 65 years for controls\n* Willing and able to provide consent\n* Diagnosis of systemic light chain amyloidosis by standard criteria (see below) and in hematological remission (normal serum free light chain levels)\n\n  * (immunofixation of serum and urine, IgG free light chain (FLC) assay, a biopsy of fat pad\u002F bone marrow, or organ biopsy, followed by typing of the light chain using immunohistochemistry or immunogold assay with confirmation by Mass spectroscopy as needed) AND\n  * proof of cardiac involvement by AL amyloidosis\n  * abnormal cardiac biomarkers (Abnormal high sensitivity TnT 5th generation levels (\\>9 ng\u002FL: female, \\>14 ng\u002FL: male) or abnormal age appropriate N terminal pro-brain natriuretic peptide, NT-proBNP (abnormal values: \\\u003C50 years: \\>450 pg\u002Fml; 50-75 years:\\>900 pg\u002Fml; \\>75 years: \\>1800 pg\u002Fml) or\n  * abnormal echocardiogram (wall thickness \\> 12 mm) or\n  * abnormal cardiac MRI (wall thickness \\> 12 mm or extracellular volume \\> 0.35) OR\n* Diagnosis of transthyretin cardiac amyloidosis by standard criteria\n\n  * endomyocardial biopsy followed by typing of the transthyretin amyloidosis using immunohistochemistry or immunogold assay with confirmation by Mass spectroscopy as needed\n  * extracardiac biopsy with typical cardiac imaging findings, or\n  * grade 2 or grade 3 myocardial uptake of technetium-99m pyrophosphate (PYP) if AL amyloidosis is excluded\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Severe claustrophobia despite use of sedatives\n* Decompensated heart failure (unable to lie flat for 1 hour)\n* Concomitant non-ischemic non-amyloid heart disease (valvular heart disease or dilated cardiomyopathy)\n* Severe valve stenosis or regurgitation in the aortic, mitral or tricuspid valves, including prior valve replacement\n* Severe pulmonary artery hypertension\n* Severe lung disease\n* Known obstructive epicardial coronary artery disease with stenosis \\> 50% in any single territory\n* Prior cardiac surgery\n* Regional wall motion abnormality on echocardiogram\n* Left ventricular ejection fraction \\\u003C 40%\n* Pregnant state\n* Documented allergy to N-13 ammonia or Definity\n* Contraindications to DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension:\n\n  o Patients with known or suspected Right-to-left, bi-directional, or transient right-to-left cardiac shunts, Hypersensitivity to perflutren\n* Contraindications or challenges to sonotherapy\n\n  * Severe electrolyte abnormalities\n  * QTc prolongation (values are greater than 450 milliseconds in males and greater than 470 milliseconds in females)\n  * BMI \\> 35 kg\u002Fm2\n  * Documented intracardiac thrombus\n  * Atrial fibrillation not on anticoagulation\n  * Prior history of stroke\n* Any other reason determined by the investigator that makes a subject a poor candidate for ultrasound therapy","90 Years",{"count":165,"type":21},[226],"PHASE4","This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in myocardial blood flow, systolic and diastolic function before and after sonotherapy.",[26],"2025-11-13",{"date":231,"type":40},"2025-11-14",{"date":233,"type":40},"2023-08-31",{"date":235,"type":21},"2027-04-30",{"name":237,"class":47},"Brigham and Women's Hospital",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":113,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":245,"targetDuration":166,"studyType":22,"phases":4,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":83},"100584280","essen-amyloidosis-registry-100584280","NCT06887283","Essen Amyloidosis Registry","EAR","Inclusion Criteria:\n\n* Suspected or confirmed amyloidosis (any)\n* Written informed consent to participate in the study\n* Age 18 years and above\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Lack of written informed consent",{"count":246,"type":21},400,"The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis. The registry aims to improve the understanding of disease progression, diagnostic pathways, and treatment outcomes. The registry is hosted at the University Hospital Essen and follows patients longitudinally. Inclusion is open to all patients with suspected or confirmed amyloidosis who provide informed consent.",[249,26],"Amyloidosis; Systemic",[31,251,252,253,254],"Transthyretin","Light chain amyloidosis","Neuropathy","Cardiomyopathy","2025-08-15",{"date":257,"type":40},"2025-08-21",{"date":259,"type":40},"2024-05-08",{"date":261,"type":21},"2029-07-01",{"name":156,"class":47},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":271,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":274,"conditions":275,"keywords":289,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":48},"100578603","characterization-of-patients-with-cardiomyopathy-to-identify-critical-patients-candidates-for-cardiac-transplantation-100578603","NCT06813443","Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation","Clinical, Instrumental, and Molecular (Circulating and Tissue microRNAs) Characterization of Patients With Cardiomyopathy to Identify Critical Patients With Severe Organ Failure to be Candidates for Cardiac Transplantation","CMPMIRNA","Inclusion Criteria:\n\n* Patients diagnosed with CMP according to current international guidelines\n* Age ≥ 12 years at the time of diagnosis\n* Obtaining informed consent from the patient and the parent or legal guardian (in the case of patients aged \\\u003C 18 years)\n\nExclusion Criteria:\n\n* none","12 Years",{"count":273,"type":21},700,"The study aims to identify new diagnostic and prognostic markers for CMP that can help predict disease progression. In particular, the study will focus on microRNAs (miRNAs) and spatial transcriptomics, which are emerging techniques that may provide insights into the underlying disease mechanisms. By understanding these markers, the investigators hope to improve the way the investigators diagnose and manage CMP, particularly in terms of predicting progression to heart failure or heart transplantation.\n\nThe study will evaluate patients with hypertrophic cardiomyopathy (e.g., sarcomeric forms, Anderson-Fabry disease, AL, and TTR cardiac amyloidosis), dilated cardiomyopathy and arrhythmogenic cardiomyopathy. These patients will undergo clinical evaluations, including ECG, echocardiograms, CMR, biopsy analysis, and genetic testing, as well as molecular studies such as transcriptomics and miRNA analysis. This comprehensive approach aims to identify potential new biomarkers for diagnosing and predicting the disease course.",[143,26,276,277,141,278,279,280,281,282,139,283,284,285,286,287,288],"Fabry Disease","Arrhythmogenic Cardiomyopathy","Laminopathies","Dystrophia Myotonica","Mitochondrial Cardiomyopathy","Dilated Cardiomyopathy","Sudden Cardiac Death","Glycogen Storage Disease","Infiltrative Cardiomyopathy","Cardiac Magnetic Resonance Imaging","Electrocardiogram","Micro RNA","Echocardiogram",[290,291,292,293,294,295,296,297,298],"cardiomyopathy","cardiac amyloidosis","Fabry disease","hypertrophic cardiomyopathy","dilated cardiomyopathy","sudden cardiac death","arrhythmogenic cardiomyopathy","heart failure","heart transplantation","2025-02-03",{"date":301,"type":40},"2025-02-07",{"date":303,"type":40},"2023-02-13",{"date":305,"type":21},"2027-12-14",{"name":307,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":4,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":315,"maxAge":4,"enrollmentInfo":316,"targetDuration":318,"studyType":22,"phases":4,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":83},"100407609","cardiac-amyloidosis-in-hfpef-100407609","NCT04587648","Cardiac Amyloidosis in HFpEF","Cardiac Amyloidosis in Heart Failure Patients With Preserved Ejection Fraction","Inclusion Criteria:\n\n* Patient is ≥ 60 years old or 50 y\u002Fo with carpal tunnel syndrome or spinal stenosis\n* Patient has been diagnosed as HFpEF in their medical history or newly diagnosed as HFpEF. They have HF symptoms with NYHA Classification of I-IV when diagnosis. The criteria of HFpEF is according to our previous studies.\n* More than 50% of them have LVPW ≥12mm (when diagnosis).\n* Written informed consent could be obtained.\n\nExclusion Criteria:\n\n* Patients unwilling to join this projects.\n* Patients with unstable coronary artery disease, plan to receive coronary intervention within months.\n* Patients has previous history of HFrEF with a LVEF \\\u003C40%.","60 Years",{"count":317,"type":21},250,"5 Years","Heart failure with preserved ejection fraction (HFpEF) accounts for half of heart failure cases with heterogenous cause and variable presentations. The diagnosis of HFpEF required clinical signs and symptoms of HF, normal left ventricular ejection fraction (LVEF) and evidence of diastolic dysfunction. No treatment has been shown in recent major clinical trials having benefits in these patients. One major reason of the poor response to medical treatment is the heterogeneity of HFpEF, which contains many different underline causes. To identify the underlying causes of HFpEF may improve the diagnosis and treatment in these patients.\n\nAge-related amyloid deposition has first been reported in 1876 and the following autopsy studies showed the prevalence of senile cardiac amyloid is up to 25%. Recently, it has been recognized that the deposits in senile cardiac amyloid are derived from wild-type transthyretin (TTR). Transthyretin amyloidosis cardiac amyloidosis (ATTR CA) is caused by myocardial deposition of misfolded transthyretin protein. There are 2 types of ATTR classified by genetic mutation including wild-type ATTR (ATTRwt) and familial cardiac amyloid caused by TTR mutation (ATTRm).\n\nMultimodality techniques have been developed to assist in the diagnosis of the diagnosis of TTR. Among them, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy is a non-invasive test and it can diagnose TTR from other cause diverse form of cardiac amyloidosis and cardiomyopathy. In the study of Gonzalez-Lopez et al, in 120 HFpEF patients, 16 (13.3%) had positive 99mTc-DPD scan. Four patients with positive 99mTc-DPD scan received endomyocardial biopsy and confirmed cardiac amyloid deposition.\n\nATTRwt could be an important cause of HFpEF and it was often under diagnosed. A recent study in Spain reported that 13% of patents over age of 60 years with HFpEF and left ventricular wall thickness of 12mm or more had ATTRwt. However, the prevalence of ATTRwt among patients with HFpEF is not well-established in Taiwan and Asia. The aim of this study is to determine the prevalence, clinical characteristics, risk factors and outcomes of ATTRwt related HFpEF patients in Taiwan.",[321,26],"Heart Failure With Preserved Ejection Fraction","2024-07-03",{"date":324,"type":40},"2024-07-05",{"date":326,"type":40},"2019-08-01",{"date":328,"type":21},"2025-12-31",{"name":330,"class":47},"National Taiwan University Hospital"]